imidazole-1-carboxylic acid {4-methyl-5-[2-cyclobutyl-pyrimidin-4-yl]-thiazol-2-yl}-amide | 1163707-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: imidazole-1-carboxylic acid {4-methyl-5-[2-cyclobutyl-pyrimidin-4-yl]-thiazol-2-yl}-amide
• 英文别名: N-[5-(2-cyclobutylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]imidazole-1-carboxamide
• CAS: 1163707-07-0
• 化学式: C₁₆H₁₆N₆OS
• 分子量: 340.409
• InChiKey: VGLZYPKOKXYIDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  imidazole-1-carboxylic acid {4-methyl-5-[2-cyclobutyl-pyrimidin-4-yl]-thiazol-2-yl}-amide 、 L-脯氨酰胺 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-cyclobutyl-pyrimidin-4-yl]-thiazol-2-yl}-amide)
  参考文献：
  名称：

  Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

  摘要：

  Phosphatidylinositol-3-kinase alpha (PI3K alpha) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3K alpha, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.007
• 作为产物：
  描述：

  5-乙酰基-2-氨基-4-甲基噻唑 在 sodium hydroxide 作用下， 以 乙二醇甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 imidazole-1-carboxylic acid {4-methyl-5-[2-cyclobutyl-pyrimidin-4-yl]-thiazol-2-yl}-amide
  参考文献：
  名称：

  Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

  摘要：

  Phosphatidylinositol-3-kinase alpha (PI3K alpha) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3K alpha, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.007

文献信息

• Organic Compounds
  申请人：Caravatti Giorgio

  公开号：US20090163469A1

  公开（公告）日：2009-06-25

  The present invention relates to compounds of formula I and its salts, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及公式I的化合物及其盐，其中取代基如描述中所定义，以及该化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。